Current directions in tau research: Highlights from Tau 2020

Claire Sexton¹, Heather Snyder¹, Dirk Beher², Adam L Boxer³, Pat Brannelly⁴, Jean-Pierre Brion⁵, Luc Buée⁶, Angela M Cacace⁷, Gaël Chételat⁸, Martin Citron⁹, Sarah L DeVos¹⁰, Kristophe Diaz¹¹, Howard H Feldman¹², Bess Frost¹³, Alison M Goate¹⁴, Michael Gold¹⁵, Bradley Hyman¹⁶, Keith Johnson¹⁷, Celeste M Karch¹⁸, Diana R Kerwin¹⁹, Walter J Koroshetz²⁰, Irene Litvan²¹, Huw R Morris²², Catherine J Mummery²³, James Mutamba²⁴, Marc C Patterson²⁵, Yakeel T Quiroz²⁶, Gil D Rabinovici²⁷, Amy Rommel²⁸, Melanie B Shulman²⁹, Leticia M Toledo-Sherman²⁸, Stacie Weninger³⁰, Kristin R Wildsmith³¹, Susan L Worley³², Maria C Carrillo¹

Affiliations

¹ Alzheimer's Association, Chicago, Illinois, USA.
² Asceneuron, Lausanne, Switzerland.
³ Memory and Aging Center, Department of Neurology, University of California, San Francisco, San Francisco, California, USA.
⁴ Alzheimer's Disease Data Initiative, Kirkland, WI, USA.
⁵ Laboratory of Histology, Neuroanatomy and Neuropathology, Faculty of Medicine, Université Libre de Bruxelles, Brussels, Belgium.
⁶ Univ Lille, Inserm, CHU-Lille, Lille Neuroscience and Cognition, Place de Verdun, Lille, France.
⁷ Neuroscience and Platform Biology, Arvinas, New Haven, USA.
⁸ Normandie Univ, UNICAEN, INSERM, U1237, PhIND "Physiopathology and Imaging of Neurological Disorders", Institut Blood and Brain @ Caen-Normandie, Cyceron, Caen, France.
⁹ Neuroscience TA, Braine l'Alleud, UCB Biopharma, Brussels, Belgium.
¹⁰ Translational Sciences, Denali Therapeutics, San Francisco, California, USA.
¹¹ Cure PSP, New York, New York, USA.
¹² Alzheimer's Disease Cooperative Study, Department of Neurosciences, University of California, San Diego, La Jolla, California, USA.
¹³ Sam & Ann Barshop Institute for Longevity and Aging Studies, Glenn Biggs Institute for Alzheimer's & Neurodegenerative Disorders, Department of Cell Systems & Anatomy, University of Texas Health San Antonio, San Antonio, Texas, USA.
¹⁴ Ronald M. Loeb Center for Alzheimer's Disease, Department of Neuroscience, Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
¹⁵ AbbVie, Neurosciences Development, North Chicago, Illinois, USA.
¹⁶ Department of Neurology, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA.
¹⁷ Massachusetts General Hospital, Boston, Massachusetts, USA.
¹⁸ Department of Psychiatry, Washington University in St. Louis, St. Louis, Missouri, USA.
¹⁹ Kerwin Medical Center, University of Texas Southwestern Medical Center, Dallas, Texas, USA.
²⁰ National Institute of Neurological Disorders and Stroke, Bethesda, Maryland, USA.
²¹ Parkinson and Other Movement Disorders Center, Department of Neurosciences, University of California San Diego, San Diego, California, USA.
²² Department of Clinical and Movement Neuroscience, UCL Queen Square Institute of Neurology, London, UK.
²³ Dementia Research Centre, National Hospital for Neurology and Neurosurgery, University College London, London, UK.
²⁴ Longwood Fund, Boston, Massachusetts, USA.
²⁵ Departments of Neurology, Pediatrics and Medical Genetics, Mayo Clinic, Rochester, Minnesota, USA.
²⁶ Departments of Neurology and Psychiatry, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA.
²⁷ Memory & Aging Center, Departments of Neurology, Radiology & Biomedical Imaging, University of California San Francisco, San Francisco, California, USA.
²⁸ Tau Consortium, Rainwater Charitable Foundation, Fort Worth, Texas, USA.
²⁹ Neurodegeneration Development Unit, Biogen, Boston, Massachusetts, USA.
³⁰ FBRI, Cambridge, Massachusetts, USA.
³¹ Department of Biomarker Development, Genentech, South San Francisco, California, USA.
³² Independent science writer, Bryn Mawr, Pennsylvania, USA.

PMID: 34581500
DOI: 10.1002/alz.12452

Review

Current directions in tau research: Highlights from Tau 2020

Claire Sexton et al. Alzheimers Dement. 2022 May.

. 2022 May;18(5):988-1007.

doi: 10.1002/alz.12452. Epub 2021 Sep 28.

Authors

Affiliations

¹ Alzheimer's Association, Chicago, Illinois, USA.
² Asceneuron, Lausanne, Switzerland.
³ Memory and Aging Center, Department of Neurology, University of California, San Francisco, San Francisco, California, USA.
⁴ Alzheimer's Disease Data Initiative, Kirkland, WI, USA.
⁵ Laboratory of Histology, Neuroanatomy and Neuropathology, Faculty of Medicine, Université Libre de Bruxelles, Brussels, Belgium.
⁶ Univ Lille, Inserm, CHU-Lille, Lille Neuroscience and Cognition, Place de Verdun, Lille, France.
⁷ Neuroscience and Platform Biology, Arvinas, New Haven, USA.
⁸ Normandie Univ, UNICAEN, INSERM, U1237, PhIND "Physiopathology and Imaging of Neurological Disorders", Institut Blood and Brain @ Caen-Normandie, Cyceron, Caen, France.
⁹ Neuroscience TA, Braine l'Alleud, UCB Biopharma, Brussels, Belgium.
¹⁰ Translational Sciences, Denali Therapeutics, San Francisco, California, USA.
¹¹ Cure PSP, New York, New York, USA.
¹² Alzheimer's Disease Cooperative Study, Department of Neurosciences, University of California, San Diego, La Jolla, California, USA.
¹³ Sam & Ann Barshop Institute for Longevity and Aging Studies, Glenn Biggs Institute for Alzheimer's & Neurodegenerative Disorders, Department of Cell Systems & Anatomy, University of Texas Health San Antonio, San Antonio, Texas, USA.
¹⁴ Ronald M. Loeb Center for Alzheimer's Disease, Department of Neuroscience, Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
¹⁵ AbbVie, Neurosciences Development, North Chicago, Illinois, USA.
¹⁶ Department of Neurology, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA.
¹⁷ Massachusetts General Hospital, Boston, Massachusetts, USA.
¹⁸ Department of Psychiatry, Washington University in St. Louis, St. Louis, Missouri, USA.
¹⁹ Kerwin Medical Center, University of Texas Southwestern Medical Center, Dallas, Texas, USA.
²⁰ National Institute of Neurological Disorders and Stroke, Bethesda, Maryland, USA.
²¹ Parkinson and Other Movement Disorders Center, Department of Neurosciences, University of California San Diego, San Diego, California, USA.
²² Department of Clinical and Movement Neuroscience, UCL Queen Square Institute of Neurology, London, UK.
²³ Dementia Research Centre, National Hospital for Neurology and Neurosurgery, University College London, London, UK.
²⁴ Longwood Fund, Boston, Massachusetts, USA.
²⁵ Departments of Neurology, Pediatrics and Medical Genetics, Mayo Clinic, Rochester, Minnesota, USA.
²⁶ Departments of Neurology and Psychiatry, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA.
²⁷ Memory & Aging Center, Departments of Neurology, Radiology & Biomedical Imaging, University of California San Francisco, San Francisco, California, USA.
²⁸ Tau Consortium, Rainwater Charitable Foundation, Fort Worth, Texas, USA.
²⁹ Neurodegeneration Development Unit, Biogen, Boston, Massachusetts, USA.
³⁰ FBRI, Cambridge, Massachusetts, USA.
³¹ Department of Biomarker Development, Genentech, South San Francisco, California, USA.
³² Independent science writer, Bryn Mawr, Pennsylvania, USA.

PMID: 34581500
DOI: 10.1002/alz.12452

Abstract

Studies supporting a strong association between tau deposition and neuronal loss, neurodegeneration, and cognitive decline have heightened the allure of tau and tau-related mechanisms as therapeutic targets. In February 2020, leading tau experts from around the world convened for the first-ever Tau2020 Global Conference in Washington, DC, co-organized and cosponsored by the Rainwater Charitable Foundation, the Alzheimer's Association, and CurePSP. Representing academia, industry, government, and the philanthropic sector, presenters and attendees discussed recent advances and current directions in tau research. The meeting provided a unique opportunity to move tau research forward by fostering global partnerships among academia, industry, and other stakeholders and by providing support for new drug discovery programs, groundbreaking research, and emerging tau researchers. The meeting also provided an opportunity for experts to present critical research-advancing tools and insights that are now rapidly accelerating the pace of tau research.

Keywords: Alzheimer's; biomarkers; neurodegeneration; tau; therapeutics.

PubMed Disclaimer

References

REFERENCES

1. Stelzmann RA, Schnitzlein HN, Murtagh FR. An english translation of Alzheimer's 1907 paper, “über eine eigenartige erkankung der hirnrinde. Clin Anat. 1995;8(6):429-431.
1. Kidd M. Paired helical filaments in electron microscopy of Alzheimer's disease. Nature. 1963;197(4863):192-193.
1. Terry RD. The fine structure of neurofibrillary tangles in Alzheimer's disease*†‡. J Neuropathol Exp Neurol. 1963;22(4):629-642.
1. Weingarten MD, Lockwood AH, Hwo SY, Kirschner MW. A protein factor essential for microtubule assembly. Proc Natl Acad Sci U S A. 1975;72(5):1858-1862.
1. Goedert M, Wischik CM, Crowther RA, Walker JE, Klug A. Cloning and sequencing of the cDNA encoding a core protein of the paired helical filament of Alzheimer disease: identification as the microtubule-associated protein tau. Proc Natl Acad Sci U S A. 1988;85(11):4051-4055.

Publication types

Actions
Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions

Grants and funding

R01 AG058778/NS/NINDS NIH HHS/United States

LinkOut - more resources

Full Text Sources
- Wiley

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Current directions in tau research: Highlights from Tau 2020

Affiliations

Current directions in tau research: Highlights from Tau 2020

Authors

Affiliations

Abstract

References

REFERENCES

Publication types

MeSH terms

Substances

Grants and funding

LinkOut - more resources

Full Text Sources